The UK Health Security Agency (UKHSA) has an active programme to promote awareness of tick-borne diseases among local authorities, health professionals and the public by 2025 in line with the Third National Adaptation Programme. This includes Lyme disease and tick-borne encephalitis. UKHSA has worked to develop a toolkit for local authorities and key stakeholders to raise awareness of the potential risks created by ticks and tick-borne disease, a copy of which is attached. UKHSA also publishes Lyme disease data on Fingertips, which is an open access public health data platform which allows the public, health professionals, and local authorities to view trends, compare indicators and understand the incidence of Lyme disease in their area.<\/p>
Clinicians are also engaged via teaching sessions for General Practitioners, seminars for infection specialists, and briefing notes to notify clinicians of the possibility of tick-borne diseases, with detail of compatible signs and symptoms. Disease messaging is shared through media, social, and stakeholder channels at a national and regional level, such as the #BeTickAware campaign which aims to raise awareness in the population, including those at risk of exposure through work or leisure.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/1700670/answer/attachment/1", "fileName" : {"_value" : "Be_tick_aware_toolkit.pdf"} , "title" : "Be_tick_aware_toolkit"} , "dateOfAnswer" : {"_value" : "2024-04-23", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-23T11:38:44.92Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Ticks"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government, following the publication of the UK Health Security Agency report Health Effects of Climate Change (HECC) in the UK: State of the evidence 2023 in January, what steps they are taking to inform health professionals of the heightened risk to public health of (1) Lyme disease, and (2) emerging tick-borne diseases, including tick-borne encephalitis, from an increase in the UK distribution of tick species as a result of a warming climate; and what advice are they providing to those exposed to this risk through work or leisure.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3310", "label" : {"_value" : "Biography information for The Earl of Caithness"} } , "tablingMemberPrinted" : [{"_value" : "The Earl of Caithness"} ], "uin" : "HL3728"} , {"_about" : "http://data.parliament.uk/resources/1700671", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1700671/answer", "answerText" : {"_value" : "
We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2024-04-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL3730"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-22T15:15:21.697Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Shortages"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what steps they are taking to mitigate the current shortage of the psychotropic medication Olanzapine, Risperidone and Haloperidol following the sudden departure of two generic manufacturers from the UK market.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1138", "label" : {"_value" : "Biography information for Lord Carlile of Berriew"} } , "tablingMemberPrinted" : [{"_value" : "Lord Carlile of Berriew"} ], "uin" : "HL3729"} , {"_about" : "http://data.parliament.uk/resources/1699944", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1699944/answer", "answerText" : {"_value" : "
National Health Service dental contract holders are awarded funding at the start of each financial year, based on the contracted number of Units of Dental Activity (UDA). Contractors are required to deliver at least 96% of their contracted activity on an annual basis. Where this does not occur, the NHS reclaims the difference between the monies paid to contractors and the value of work which has been delivered. NHS England will encourage commissioners and contractors to work together to resolve underperformance against the contract at the mid-year review point, or by voluntarily rebasing their contract in the first instance. Where this is not possible, and where there have been three consecutive years of persistent underperformance, commissioners will be able to rebase contracts to the highest level of UDAs delivered over the three-year period from the following year, and recommission unused activity to other providers.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4117", "label" : {"_value" : "Biography information for Andrea Leadsom"} } , "answeringMemberConstituency" : {"_value" : "South Northamptonshire"} , "answeringMemberPrinted" : {"_value" : "Andrea Leadsom"} , "dateOfAnswer" : {"_value" : "2024-04-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-17T15:52:47.447Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Dental Services: Standards"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will introduce a system of redress for NHS dentists that fulfil less than (a) 80%, (b) 50% and (c) 10% of their performance target.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4098", "label" : {"_value" : "Biography information for Dr Thérèse Coffey"} } , "tablingMemberConstituency" : {"_value" : "Suffolk Coastal"} , "tablingMemberPrinted" : [{"_value" : "Dr Thérèse Coffey"} ], "uin" : "21013"} , {"_about" : "http://data.parliament.uk/resources/1699968", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1699968/answer", "answerText" : {"_value" : "
Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors\u2019 payments, and where they have been overpaid, we decrease payments.<\/p>
Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-04-19", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "20979"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-19T09:54:36.01Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pharmacy: Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of medication costs on community pharmacies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"} } , "tablingMemberConstituency" : {"_value" : "Gosport"} , "tablingMemberPrinted" : [{"_value" : "Dame Caroline Dinenage"} ], "uin" : "20988"} , {"_about" : "http://data.parliament.uk/resources/1699969", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1699969/answer", "answerText" : {"_value" : "
As part of the Community Pharmacy Contractual Framework five-year deal, we committed £2.6 billion every year to community pharmacy, and agreed not to recover £212 million in over delivered fees and margin from community pharmacies in recent years. In addition, we are now investing up to £645 million across 2023/24 and 2024/25 in Pharmacy First, for more blood pressure checks and more contraception consultations in pharmacy. We have begun the consultation with Community Pharmacy England on the national funding and contractual framework arrangements for 2024/25.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4117", "label" : {"_value" : "Biography information for Andrea Leadsom"} } , "answeringMemberConstituency" : {"_value" : "South Northamptonshire"} , "answeringMemberPrinted" : {"_value" : "Andrea Leadsom"} , "dateOfAnswer" : {"_value" : "2024-04-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-18T16:00:23.64Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pharmacy: Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she plans to increase core community pharmacy funding.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"} } , "tablingMemberConstituency" : {"_value" : "Gosport"} , "tablingMemberPrinted" : [{"_value" : "Dame Caroline Dinenage"} ], "uin" : "20989"} , {"_about" : "http://data.parliament.uk/resources/1699970", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1699970/answer", "answerText" : {"_value" : "
Pharmacy First was launched on 31 January 2024, and as the service embeds, we will monitor and evaluate the service, and keep the conditions covered by Pharmacy First under review.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4117", "label" : {"_value" : "Biography information for Andrea Leadsom"} } , "answeringMemberConstituency" : {"_value" : "South Northamptonshire"} , "answeringMemberPrinted" : {"_value" : "Andrea Leadsom"} , "dateOfAnswer" : {"_value" : "2024-04-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-18T16:57:21.523Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pharmacy: Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she plans to increase the scope of the Pharmacy First programme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"} } , "tablingMemberConstituency" : {"_value" : "Gosport"} , "tablingMemberPrinted" : [{"_value" : "Dame Caroline Dinenage"} ], "uin" : "20990"} , {"_about" : "http://data.parliament.uk/resources/1699971", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1699971/answer", "answerText" : {"_value" : "
The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:<\/p>
<\/p>
https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy<\/a><\/p> <\/p> The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.<\/p> <\/p> Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK\u2019s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.<\/p> In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.<\/p> We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.<\/p> The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE\u2019s evaluation, in line with NICE\u2019s published topic selection manual.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-22", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "20992"}
, {"_value" : "20993"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-22T11:22:39.867Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Equipment"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she plans to develop a Priority Review programme for medical devices.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "tablingMemberConstituency" : {"_value" : "Gosport"}
, "tablingMemberPrinted" : [{"_value" : "Dame Caroline Dinenage"}
], "uin" : "20991"}
, {"_about" : "http://data.parliament.uk/resources/1699972", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1699972/answer", "answerText" : {"_value" : " The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:<\/p> <\/p>